

CURRICULUM VITAE Marc Ferrante

Last Name: FERRANTE
First Names: Marc Armand Guy
Place of birth: Vilvoorde, Belgium
Date of birth: February 5, 1977
Work Address: Department of Gastroenterology and Hepatology
University Hospitals Leuven – KU Leuven
Herestraat 49
B-3000 Leuven, Belgium
Tel: +32-(0)16-34.42.25
Fax: +32-(0)16-34.44.19
Email: marc.ferrante@uzleuven.be

Civil Status: Married with two children
Citizenship: Belgian



Career

Since 2021: Full Professor of Gastroenterology and Hepatology, KU Leuven, Belgium
2017-2021: Associate Professor of Gastroenterology and Hepatology, KU Leuven, Belgium
Since 2014: Senior Clinical Investigator (Research Foundation – Flanders, FWO)
2013-2017: Assistant Professor of Gastroenterology and Hepatology, KU Leuven, Belgium
2010-2012: Post-Doc: “Influence of microbiota on intestinal stem cell behavior, differentiation and migration in patients with inflammatory bowel diseases”
Hubrecht Institute, Clevers Group, Utrecht, The Netherlands
TARGID, KU Leuven, Belgium

2009-2010: Residency in Gastroenterology in the University Hospitals Leuven, Leuven, Belgium
2008-2009: Residency in Gastroenterology in the Onze-Lieve-Vrouwziekenhuis, Aalst, Belgium
2002-2008: Residency in Internal Medicine in the University Hospitals Leuven, Leuven, Belgium
2001: Elective training Obstetrics in Stellenbosh, South Africa (05/2001-07/2001)
Elective training Paediatrics in Johannesburg, South Africa (03/2001-05/2001)

Education

2018-2019: Management and leadership for physicians, KU Leuven / U Gent, Belgium
2002-2010: Certified Specialist in Gastroenterology, KU Leuven, Belgium
2006: Laboratory Animal Research course, KU Leuven, Belgium
2004-2007: Ph.D. Medical Sciences: “Assessing and predicting disease progression in IBD: a clinical and molecular approach”, KU Leuven, Belgium
1995-2002: Doctor in Medicine, Surgery and Obstetrics (M.D.) cum laude, KU Leuven, Leuven, Belgium
1989-1995: High School Sciences-Mathematics, Jan Van Ruusbroeckcollege, Laken, Belgium

Posts of responsibility

Since 2020: Member of the BIRD Scientific Committee (SciCom)
Since 2019: Member of the ECCO Scientific Committee (SciCom)
2015-2019: Member and subsequently chair of the ECCO Clinical Committee (ClinCom)
Since 2014: Coach of the clinical fellows in training
2013-2020: Board member and treasurer of Belgian IBD Research and Development (BIRD)
Since 2011: Member of the editorial board of *Journal of Crohn's and Colitis*
Since 2008: Co-chair of IBD sessions during UEGW, ECCO and Belgian Week congresses
Since 2008: Abstract reviewer for ECCO, UEGW, and WCOG congresses
2006-2011: Founding member, deputy chair and subsequently chair of the Young European Crohn's and Colitis Organisation (Y-ECCO)
Since 2005: Mentor for scientific thesis of several last year students and fellows
1999-2000: Head of the student organization Medica, representative of all medical students
KU Leuven, Belgium
1996-1999: Principal director of AKABE Aalst (boy scouts & girls for people with a handicap)

Awards, Distinctions

- 2020: H2020 / IMI IBD project leader (458184 Euro)
2020: SBO FWO Grant together with Zeger Debyser (2578500 Euro)
2020: Abbvie Scientific chair in IBD together with Séverine Vermeire (180000 Euro)
2020: Pfizer Scientific chair in IBD together with Séverine Vermeire (180000 Euro)
2019: Biogen Fellowship support (180000 Euro)
2019: Amgen Doctoral research on quality of care (60000 Euro)
2019: Helmsley Charitable Trust Grant together with Guy Boeckxstaens (2998860 USD)
2018: Pfizer Independent Grant for Learning & Change (149303 USD)
2018: Takeda Scientific chair in IBD together with Séverine Vermeire (180000 Euro)
2018: Janssen Scientific chair in IBD together with Séverine Vermeire (180000 Euro)
2015: Takeda Scientific chair in IBD together with Séverine Vermeire (180000 Euro)
2014: United European Gastroenterology Rising Star Award
2012: Laureate Research Award Belgian Society of Gastrointestinal Endoscopy
For evaluating predictors of post-operative recurrence (5000 Euro)
Laureate CREA Research Grant KU Leuven
For stem cell research (160000 Euro)
Laureate Research Grant European Crohn's and Colitis Organisation (ECCO)
For stem cell research (15000 Euro)
2011: Laureate Research Award van Genechten-Paternoster en Prof G Vantrappen
For research on the use of infliximab in ulcerative colitis (12.000 Euro)
2010: Laureate Research Award Willy and Marcy De Vooght Foundation
For stem cell research (20000 Euro)
Laureate Research Award Flemish Association for Gastroenterology
For stem cell research (1400 Euro)
Laureate Research Award Belgian Society of Gastrointestinal Endoscopy
For defining endoscopic response in Crohn's disease (5000 Euro)
2008: Laureate Research Award Flemish Crohn's and Colitis organization
For a prospective study on the role of myenteric plexitis (3000 Euro)
2007: Prize for best poster on IBD at UEGW 2007
Third poster prize at Falk Symposium "Achievements in Research and Clinical Practice" (250 Euro)
2005: Laureate Research Award Flemish Association for Gastroenterology (700 Euro)
Best oral presentation "Clinical research in internal Medicine"

PhD programs

- Since 2021: Promotor PhD project An Outtier: From drug development to registration: optimalization of flow processes
Since 2019: Promotor PhD project Liselotte Fierens: Quality of care in inflammatory bowel diseases
Since 2019: Promotor PhD project Wannee Kantasiripitak: Model-based therapeutic drug monitoring to improve treatment outcome of biologicals in individual patients with chronic inflammatory diseases
Since 2019: Co-Promotor PhD project Mona Farhadipour: Chemosensory receptors in the human gut determine enterendocrine cell fate to regulate the release of appetite regulating hormones during obesity
Since 2017: Promotor PhD project Kaline Arnauts: The effects of microbiota on epithelial cells in ulcerative colitis (Public defense 22-11-2021)
Since 2017: Promotor PhD project Annick Moens: Safety of biological therapies in inflammatory bowel diseases (Public defense 24-09-2021)
2015-2019: Promotor PhD project Bram Verstockt: Predicting outcomes of inflammatory bowel diseases: creating opportunities for personalized medicine (Public defense 04-09-2019)
2014-2018: Co-Promotor PhD project Sumin Bian: Inflammatory Bowel Disease: Towards Advanced Monitoring of Biologicals and Anti-biological Antibodies (Public defense 30-08-2018)
Since 2014: Co-Promotor PhD project Sofie Coenen: Quality of care in inflammatory bowel diseases

- 2013-2018: Co-Promotor PhD project Iris Detrez: Development, validation and clinical application of assays in order to perform blood concentration measurements of biologicals (Public defense 25-09-2018)
- 2011-2015: Co-Promotor PhD project Bart Lemmens: Histological and microbiological correlations in established chronic inflammatory bowel diseases
- 2012-2017: Promotor PhD project Manuel Noben: Intestinal organoids in inflammatory bowel diseases (Public defense 26-09-2017)

Language skills

Dutch: native language
 English and French: fluent
 German and Italian: basic

Computer skills

Microsoft office (Word, Excel, Powerpoint, Access)
 SPSS
 Reference Manager

Experience in clinical trials

Since 2014: Central endoscopy reader of several multi-centre clinical trials
 Since 2011: Principal investigator and sub-investigator of several multi-centre clinical trials
 Since 2009: Principal investigator and sub-investigator of several local clinical trials

Some recent clinical trials

Role	Therapeutic area	Type	Year started	Status
PI	Crohn's disease	Interventional; AbbVie phase 3: risankizumab M16-006 and -000	2019	Ongoing
PI	Ulcerative colitis	Interventional; Lilly phase 3: mirikizumab AMAN-AMBG	2018	Ongoing
PI	Crohn's disease	Interventional; Cellerix phase 3: darvadstrocel ADMIRE 2	2017	Ongoing

Training for clinical trials

Interactive GCP-Workshop for Experienced Researches (EF-GCP): 8 February 2012
 Last online GCP training (The Global Health Network): 28 May 2021

Miscellaneous

Promotor of Hans Clevers for a honorary doctorate at KU Leuven in 2021
 Occasional reviewer for *Nature*, *New England Journal of Medicine*, *Human Molecular Genetics*, *Gut*, *American Journal of Gastroenterology*, *British Journal of Surgery*, *Inflammatory Bowel Diseases*, *Digestive & Liver Disease*, *European Journal of Gastroenterology and Hepatology*, *Journal of Crohn's and Colitis*, *PloS One*, *Journal of Pediatric Gastroenterology and Nutrition*, *Inflammatory Bowel Disease Monitor* and *Acta Gastroenterologica Belgica*.
 Member of the organizing committee for the ECCO congress 2022
 Member of the organizing committee of the BIRD symposia in 2018 and 2019
 Organizer of the IBD sessions at the *Belgian Week of Gastroenterology* in 2018
 Individual member of the *European Crohn's and Colitis Organisation* (ECCO) since 2008
 Member of the Belgian IBD Research and Development group since 2006
 Participant to the ECCO student course, Amsterdam 2006
 Participant to the Young Clinician Program, World Congress of Gastroenterology, Montreal 2005

PUBLICATION LIST Marc Ferrante

Peer reviewed journals:

1. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, **Ferrante M**, Hiele M, Bueno De Mesquita M, D'Hoore A, Penninckx F, Rutgeerts P. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. *Aliment Pharmacol Ther* 2004; 19: 749-754.
2. **Ferrante M**, De Hertogh G, Penninckx F, Van Assche G. Protein-losing enteropathy in Crohn's disease. *Clin Gastroenterol Hepatol* 2005; 3: A25.
3. Hlavaty T, Pierik M, Henckaerts L, **Ferrante M**, Joossens S, Van Schuerbeek N, Noman M, Rutgeerts P, Vermeire S. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. *Aliment Pharmacol Ther* 2005; 22: 613-626.
4. **Ferrante M**, Geubel AP, Fevery J, Marogy G, Horsmans Y, Nevens F. Hereditary hyperferritinaemia-cataract syndrome: a challenging diagnosis for the hepatogastroenterologist. *Eur J Gastroenterol Hepatol* 2005; 17: 1247-1253.
5. Vermeire S, Pierik M, Hlavaty T, Claessens G, Van Schuerbeek N, Joossens S, **Ferrante M**, Henckaerts L, Bueno de Mesquita M, Vlietinck R, Rutgeerts P. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. *Gastroenterology* 2005; 129: 1845-1853.
6. Hlavaty T, Persoons P, Vermeire S, **Ferrante M**, Pierik M, Van Assche G, Rutgeerts P. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease. *Inflamm Bowel Dis* 2006; 12: 199-204.
7. **Ferrante M**, Nevens F, Craninckx M, Fevery J. De ziekte van Gaucher (type I). Een zeldzame stapelingsziekte, soms pas op volwassen leeftijd symptomatisch. *Tijdschrift voor Geneeskunde* 2005; 9: 691-699.
8. **Ferrante M**, De Hertogh G, Hlavaty T, D'Haens G, Penninckx F, D'Hoore A, Vermeire S, Rutgeerts P, Geboes K, Van Assche G. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. *Gastroenterology* 2006; 130: 1595-1606.
9. Moskovitz DN, Van Assche G, Maenhout B, Arts J, **Ferrante M**, Vermeire S, Rutgeerts P. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. *Clin Gastroenterol Hepatol* 2006; 4: 760-765.
10. **Ferrante M**, Pierik M, Henckaerts L, Joossens M, Claes K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, Van Assche G, Vermeire S. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. *Inflamm Bowel Dis* 2006; 12: 870-878.
11. **Ferrante M**, Penninckx F, De Hertogh G, Geboes K, D'Hoore A, Noman M, Vermeire S, Rutgeerts P, Van Assche G. Protein-losing enteropathy in Crohn's disease. *Acta Gastroenterol Belg* 2006; 69: 384-389.
12. **Ferrante M**, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijis I, De Hertogh G, Hoffman I, Geboes K, Rutgeerts P. Predictors of early response to infliximab in patients with ulcerative colitis. *Inflamm Bowel Dis* 2007; 13: 123-128.
13. Hlavaty T, **Ferrante M**, Henckaerts L, Pierik M, Rutgeerts P; Vermeire S. Predictive model for outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. *Inflamm Bowel Dis* 2007; 13: 372-379.
14. **Ferrante M**, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. *Gut* 2007; 56: 1394-1403.
15. Henckaerts L, Pierik M, Joossens M, **Ferrante M**, Rutgeerts P, Vermeire S. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. *Gut* 2007; 56: 1536-1542.
16. **Ferrante M**/Declerck S, De Hertogh G, Van Assche G, Geboes K, Rutgeerts P, Penninckx F, Vermeire S, D'Hoore A. Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. *Inflamm Bowel Dis* 2008; 14: 20-28.
17. Katsanos K, Cavalier E, **Ferrante M**, Van Hauwaert V, Henckaerts L, Schnitzler F, Katsaraki A, Noman M, Vermeire S, Tsianos EV, Rutgeerts P, Chapelle J-P, Van Assche G. Intravenous iron therapy restores functional iron deficiency induced by infliximab. *J Crohns Colitis* 2007; 1: 97-105.

18. Burke JP/**Ferrante M**, Dejaegher K, Watson RWG, Docherty NG, De Hertogh G, Vermeire S, Rutgeerts P, D'Hoore A, Penninckx F, Geboes K, Van Assche G, O'Connell PR. Transcriptomic analysis of intestinal fibrosis associated gene expression in response to medical therapy in Crohn's disease. *Inflamm Bowel Dis* 2008; 14: 1197-1204.
19. **Ferrante M**, Declerck S, Coopmans T, De Hertogh G, Van Assche G, Penninckx F, Rutgeerts P, Geboes K, D'Hoore A, Vermeire S. Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: a role for serological markers and microbial pattern recognition receptor genes. *J Crohns Colitis* 2008; 2: 142-151.
20. Bueno de Mesquita M, **Ferrante M**, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G, Rutgeerts P, Vermeire S, Hoffman I. Clustering of (auto)immune diseases with early -onset and complicated inflammatory bowel disease. *Eur J Pediatr* 2009; 168: 575-583.
21. **Ferrante M**, Vermeire S, Fidler H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D'Hoore A, Van Steen K, Geboes K, Penninckx F, Rutgeerts P. Long-term outcome after infliximab for refractory ulcerative colitis. *J Crohns Colitis* 2008; 2: 219-225.
22. Schnitzler F, Fidler H, **Ferrante M**, Noman M, Arijis I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Long-term outcome of treatment with infliximab in 614 Crohn's disease patients: results from a single centre cohort. *Gut* 2009; 58: 492-500.
23. Fidler HH, Schnitzler F, **Ferrante M**, Noman M, Katsanos K, Segaeert S, Van Assche G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. *Gut* 2009; 58: 501-508.
24. **Ferrante M**, D'Hoore A, Vermeire S, Declerck S, Noman M, Van Assche G, Hoffman I, Rutgeerts P, Penninckx F. Corticosteroids but not infliximab increase short-term post-operative infectious complications in patients with ulcerative colitis. *Inflamm Bowel Dis* 2009; 15: 1062-1070.
25. **Ferrante M**, Vermeire S, Van Assche G, Rutgeerts P. Reply to Dr. Caprilli et al.'s letter. *J Crohns Colitis* 2009; 3: 45.
26. Schnitzler F, Fidler H, **Ferrante M**, Noman M, Arijis I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. *Inflamm Bowel Dis* 2009; 15: 1295-1301.
27. **Ferrante M**, D'Haens G, Dewit O, Baert F, Holvoet J, Geboes K, De Hertogh G, Van Assche G, Vermeire S, Rutgeerts P. Efficacy of infliximab in refractory pouchitis and Crohn's disease related complications of the pouch: a Belgian case series. *Inflamm Bowel Dis* 2010; 16: 243-249.
28. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, **Ferrante M**, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. *Gastroenterology* 2009; 137: 1628-1640.
29. Arijis I, Li K, Toedter G, Quintens R, Van Lommel L, Van Steen K, Leemans P, De Hertogh G, Lemaire K, **Ferrante M**, Schnitzler F, Thorrez L, Ma K, Song XY, Marano C, Van Assche G, Vermeire S, Geboes K, Schuit F, Baribaud F, Rutgeerts P. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. *Gut* 2009; 58: 1612-1619.
30. **Ferrante M**, D'Haens G, Rutgeerts P, Vermeire S, Van Assche G. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease). *Curr Gastroenterol Rep* 2009; 11: 504-508.
31. Bentley RW, Cleynen I, Gearry RB, Barclay ML, Rutgeerts P, Merriman TR, **Ferrante M**, Roberts RL, Vermeire S. Evidence that glioma-associated oncogene homolog 1 is not a universal risk gene for inflammatory bowel disease in Caucasians. *Genes Immun* 2010; 11: 509-514.
32. **Ferrante M**, Van Boxelaer I, De Man M, Schelfout A-M, Van Molhem Y, Hendrickx K, Vandervoort J, Van Der Spek P, Sermon F, Du Ville L, Lepoutre L. Second primary malignancies in patients with a gastrointestinal neuroendocrine tumour: a case report and review of the literature. *Acta Gastroenterol Belg* 2010; 73: 397-402.
33. Breynaert C, **Ferrante M**, Fidler H, Van Steen K, Noman M, Ballet V, Vermeire S, Rutgeerts P, Van Assche G. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. *Am J Gastroenterol* 2011; 106: 778-785.
34. Márquez L, Shen C, Cleynen I, De Hertogh G, Van Steen K, Machiels K, Perrier C, Ballet V, Organe S, **Ferrante M**, Henckaerts L, Galicia G, Rutgeerts P, Ceuppens JL, Vermeire

- S. Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis. *Gut* 2011; 61: 528-534.
35. Schnitzler F, Fidder H, **Ferrante M**, Ballet V, Noman M, Van Assche G, Spitz B, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. *Inflamm Bowel Dis* 2011; 17: 1846-1854.
 36. Sato T, Stange DE, **Ferrante M**, Vries RG, van Es JH, van den Brink S, van Houdt WJ, Pronk A, van Gorp J, Siersema PD, Clevers H. Long-term Expansion of Epithelial Organoids From Human Colon, Adenoma, Adenocarcinoma, and Barrett's Epithelium. *Gastroenterology* 2011; 141: 1762-1772.
 37. Peyrin-Biroulet L, **Ferrante M**, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB, Allez M, Danese S, Sturm A. Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease. *J Crohns Colitis* 2011; 5: 477-483.
 38. Van Assche G, **Ferrante M**, Vermeire S, Noman M, Rans K, Van der Biest L, Penninckx F, Wolthuis A, Rutgeerts P, D'Hoore A. Octreotide for the treatment of diarrhea in patients with ileal pouch anal anastomosis: a placebo controlled cross-over study. *Colorectal Dis* 2012; 14: e181-186.
 39. **Ferrante M**, Karmiris K, Newnham E, Siffledeen J, Zelinkova Z, Van Assche G, Lakatos PL, Panes J, Sturm A, Travis S, van der Woude CJ, Reinisch W, Colombel JF, Panaccione R. Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme. *J Crohns Colitis* 2012; 6: 116-131.
 40. D'Haens G, **Ferrante M**, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. *Inflamm Bowel Dis* 2012; 18: 2218-2224.
 41. Baert F, Glorieus E, Reenaers C, D'Haens G, Peeters H, Franchimont D, Dewit O, Caenepeel P, Louis E, Van Assche G; BIRD (Belgian IBD Research and Development). Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. *J Crohns Colitis* 2013; 7:154-160.
 42. **Ferrante M**, Van Assche G. Medical therapy and mucosal healing. *Curr Drug Targets* 2012; 13: 1294-1299.
 43. Perrier C, Arijis I, Staelens D, Breynaert C, Cleyne I, Covens K, **Ferrante M**, Van Assche G, Vermeire S, de Hertogh G, Schuit F, Rutgeerts P, Ceuppens JL. IL-15R α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab. *Immunology* 2013;138:47-56.
 44. Bessissow T, Lemmens B, **Ferrante M**, Bisschops R, Van Steen K, Geboes K, Van Assche G, Vermeire S, Rutgeerts P, De Hertogh G. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. *Am J Gastroenterol* 2012;107:1684-1692.
 45. **Ferrante M**, Vermeire S, Rutgeerts P. Certolizumab pegol in the treatment of Crohn's disease. *Exp Opin Biol Ther* 2013; 13: 595-605.
 46. Lemmens B, Arijis I, Van Assche G, Sagaert X, Geboes K, **Ferrante M**, Rutgeerts P, Vermeire S, De Hertogh G. Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis. *Inflamm Bowel Dis* 2013; 19: 1194-1201.
 47. Heijmans J, van Lidth de Jeude JF, Koo B-K, Rosekrans SL, Wielenga MCB, van de Wetering M, **Ferrante M**, Lee AS, Onderwater JJM, Paton JC, Paton AW, Mommaas AM, Kodach LL, Hardwick JC, Hommes DIW, Clevers H, Muncan V, van den Brink GR. ER Stress Causes Rapid Loss of Intestinal Epithelial Stemness through Activation of the Unfolded Protein Response. *Cell Reports* 2013; 3: 1128-1139.
 48. Vande Casteele N, Brex S, Declerck P, **Ferrante M**, Rutgeerts P, Vermeire S, Gils A. Letter: dry blood spots for anti-TNF treatment monitoring in IBD. *Aliment Pharmacol Ther* 2013; 37: 1024-1025.
 49. Bessissow T, Van Keerberghen CA, Van Oudenhove L, **Ferrante M**, Vermeire S, Rutgeerts P, Van Assche G. Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls. *J Crohns Colitis* 2013; 7: e580-587.

50. Bessissow T, Bisschops R, **Ferrante M**, Baert F, Van Assche G, Rutgeerts P, Vermeire S. 5-aminosalicylate is not protective from neoplasia in ulcerative colitis. *Am J Gastroenterol* 2013; 108: 1015.
51. Rahier JF, Dubuquoy L, Colombel JF, Jouret-Mourin A, Delos M, **Ferrante M**, Sokol H, De Hertogh G, Salleron J, Geboes K, Desreumaux P. Decreased lymphatic vessel density is associated with postoperative endoscopic recurrence in Crohn's disease. *Inflamm Bowel Dis* 2013, 19: 2084-2090.
52. Breynaert C, Dresselaers T, Perrier C, Arijis I, Cremer J, Van Lommel L, Van Steen K, **Ferrante M**, Schuit F, Vermeire S, Rutgeerts P, Himmelreich U, Ceuppens JL, Geboes K, Van Assche G. Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease. *PLoS One* 2013; 8: e68876.
53. **Ferrante M**, Colombel J-F, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang K, Cornillie F, Rutgeerts PJ, and IOIBD members. Validation of endoscopic activity scores in patients with Crohn's disease based on a post-hoc analysis of data from SONIC. *Gastroenterology* 2013; 145: 978-986.
54. Machiels K, Joossens M, Sabino J, De Preter V, Arijis I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, **Ferrante M**, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium prausnitzii* defines dysbiosis in patients with ulcerative colitis. *Gut* 2014; 63: 1275-1283.
55. Vermeire S, **Ferrante M**, Rutgeerts P. Recent advances: Personalised use of current Crohn's disease therapeutic options. *Gut* 2013; 62: 1511-1515.
56. **Ferrante M**, Vermeire S, Rutgeerts PJ. Drug safety evaluation of certolizumab pegol. *Expert Opin Drug Saf* 2013; 255-266.
57. Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, **Ferrante M**, Götz M, Katsanos KH, Kießlich R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R; ECCO. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis* 2013;7: 982-1018.
58. Billiet T, Rutgeerts P, **Ferrante M**, Van Assche G, Vermeire S. Targeting TNF-alpha for the treatment of inflammatory bowel disease. *Expert Opin Biol Ther* 2013; 14: 75-101.
59. Forni D, Cleynen I, **Ferrante M**, Cassinotti A, Cagliani R, Ardizzone S, Vermeire S, Fichera M, Lombardini M, Maconi G, de Franchis R, Asselta R, Biasin M, Clerici M, Sironi M. ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behaviour. *J Crohns Colitis* 2014, 489-494.
60. de Bruyn M, Machiels K, Vandooren J, Lemmens B, Van Lommel L, Breynaert C, Van der Goten J, Staelens D, Billiet T, De Hertogh G, **Ferrante M**, Van Assche G, Vermeire S, Opendakker G, Schuit F, Rutgeerts P, Arijis I. Infliximab Restores the Dysfunctional Matrix Remodeling Protein and Growth Factor Gene Expression in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2014, 20: 339-352.
61. Vermeire S, **Ferrante M**, Rutgeerts P. Recent advances: Personalised use of current Crohn's disease therapeutic options. *Postgrad Med J* 2014; 90: 144-148.
62. de Buck van Overstraeten A, Wolthuis AM, Vermeire S, Van Assche G, Laenen A, **Ferrante M**, Rutgeerts P, D'Hoore A. Long-term functional outcome after ileal pouch anal anastomosis in 191 patients with ulcerative colitis. *J Crohns Colitis* 2014, 8: 1261-1266.
63. de Bruyn M, Arijis I, Wollants WJ, Machiels K, Van Steen K, Van Assche G, **Ferrante M**, Rutgeerts P, Vermeire S, Opendakker G. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis. *Inflamm Bowel Dis* 2014; 20: 1198-1207.
64. Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernelle G, Jürgens M, **Ferrante M**, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G. Withdrawal of Immunomodulators After Co-treatment Does not Reduce Trough Level of Infliximab in Patients with Crohn's Disease. *Clin Gastroenterol Hepatol* 2015; 13: 514-521.
65. Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, Wolthuis A, Van Assche G, Noman M, Hoffman I, D'Hoore A, Gils A, Rutgeerts P, **Ferrante M**. A Panel to Predict Long-term Outcome of Infliximab Therapy for Patients with Ulcerative Colitis. *Clin Gastroenterol Hepatol* 2015; 13: 531-538.
66. Billiet T, **Ferrante M**, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. *Curr Gastroenterol Rep* 2014; 16: 416.

67. Baert F, Vande Casteele N, Tops S, Noman M, Van Assche G, Rutgeerts P, Gils A, Vermeire S, **Ferrante M**. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. *Aliment Pharmacol Ther* 2014; 40: 1324-1332.
68. Øresland T, Bemelman WA, Sampietro GM, Spinelli A, Windsor A, **Ferrante M**, Marteau P, Zmora O, Kotze PG, Espin-Basany E, Turet E, Sica G, Panis Y, Faerden AE, Biancone L, Angriman I, Serclova Z, de Buck van Overstraeten A, Gionchetti P, Stassen L, Warusavitarne J, Adamina M, Dignass A, Eliakim R, Magro F, D'Hoore A; European Crohn's and Colitis Organisation (ECCO). European evidence based consensus on surgery for ulcerative colitis. *J Crohns Colitis* 2015; 9: 4-25.
69. Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, **Ferrante M**. Long-Term Outcome of Patients With Crohn's Disease who Discontinued Infliximab Therapy Upon Clinical Remission. *Clin Gastroenterol Hepatol* 2015; 13: 1103-1110.
70. Lobatón T, Hoffman I, Vermeire S, **Ferrante M**, Verhaegen J, Van Assche G. Aeromonas species: an opportunistic enteropathogen in patients with inflammatory bowel diseases? A single center cohort study. *Inflamm Bowel Dis* 2015; 21: 71-78.
71. Van der Goten J, Vanhove W, Lemaire K, Van Lommel L, Machiels K, Wollants WJ, De Preter V, De Hertogh G, **Ferrante M**, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijis I. Integrated miRNA and mRNA expression profiling in inflamed colon of patients with ulcerative colitis. *PLoS One* 2014; 9: e116117.
72. Bollen L, Vande Casteele N, Peeters M, Bessonov K, Van Steen K, Rutgeerts P, **Ferrante M**, Hoylaerts MF, Vermeire S, Gils A. Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study. *Inflamm Bowel Dis* 2015; 21: 570-578.
73. Vande Casteele N, **Ferrante M**, Van Assche G, Ballet V, Compennolle G, Van Steen K, Simoens S, Rutgeerts P, Gils A, Vermeire S. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. *Gastroenterology* 2015; 148: 1320-1329.
74. Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, Karmiris K, **Ferrante M**, Gils A, Vermeire S. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial. *Gut* 2016; 65: 1126-1131.
75. Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A, **Ferrante M**, Van Assche G, Cleynen I, Vermeire S. Immunogenicity to infliximab is associated with HLA-DRB1. *Gut* 2015; 64: 1344-1345.
76. **Ferrante M**, Papamichael K, Duricova D, D'Haens G, Vermeire S, Archavlis E, Rutgeerts P, Bortlik M, Mantzaris G, Van Assche G. Systematic versus endoscopy-driven treatment with azathioprine to prevent postoperative ileal Crohn's disease recurrence. *J Crohns Colitis* 2015, 9: 617-624.
77. Lobatón T, **Ferrante M**, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2015; 42: 441-451.
78. Lobatón T, Bessissow T, De Hertogh G, Lemmens B, Maedler C, Van Assche G, Vermeire S, Bisschops R, Rutgeerts P, Bitton A, Afif W, Marcus V, **Ferrante M**. The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients. *J Crohns Colitis* 2015; 9: 846-852.
79. Vermeire S, Louis E, Dewit O, Franchimont D, Moreels T, **Ferrante M**, Rahier JF, Van Hootegeem P, De Vos M, Mana F, Baert F; Belgian IBD Research & Development (BIRD). Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD). *Acta Gastroenterol Belg* 2015;78:26-29.
80. Li Z, Vermeire S, Bullens D, **Ferrante M**, Van Steen K, Noman M, Rutgeerts P, Ceuppens JL, Van Assche G. Restoration of Foxp3+ Regulatory T-cell Subsets and Foxp3- Type 1 Regulatory-like T Cells in Inflammatory Bowel Diseases During Anti-tumor Necrosis Factor Therapy. *Inflamm Bowel Dis* 2015; 21: 2418-2428.
81. Vanhove W, Peeters PM, Staelens D, Schraenen A, Van der Goten J, Cleynen I, De Schepper S, Van Lommel L, Reynaert NL, Schuit F, Van Assche G, **Ferrante M**, De Hertogh G, Wouters EF, Rutgeerts P, Vermeire S, Nys K, Arijis I. Strong Upregulation of

- AIM2 and IFI16 Inflammasomes in the Mucosa of Patients with Active Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2015; 21: 2673-2682.
82. Bollen L, Vande Casteele N, Peeters M, Van Assche G, **Ferrante M**, Van Moerkercke W, Declerck P, Vermeire S, Gils A. The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile. *Inflamm Bowel Dis* 2015; 21: 2540-2548.
 83. de Bruyn M, Arijis I, De Hertogh G, **Ferrante M**, Van Assche G, Rutgeerts P, Vermeire S, Opendakker G. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease. *J Crohns Colitis* 2015; 9: 1079-1087.
 84. Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, **Ferrante M**, Van Assche G, Vermeire S. A matrix-based model predicts primary response to infliximab in Crohn's disease. *J Crohns Colitis* 2015; 9: 1120-1126.
 85. de Buck van Overstraeten A, Van Hoef S, Vermeire S, **Ferrante M**, Fieuw S, Wolthuis A, Van Assche G, D'Hoore A. Postoperative inflammatory response in Crohn's patients: a comparative study. *J Crohns Colitis* 2015; 9: 1127-1131.
 86. Li Z, Vermeire S, Bullens D, **Ferrante M**, Van Steen K, Noman M, Bossuyt X, Rutgeerts P, Ceuppens JL, Van Assche G. Anti-Tumor Necrosis Factor Therapy Restores Peripheral Blood B-cell Subsets and CD40 Expression in Inflammatory Bowel Diseases. *Inflamm Bowel Dis* 2015; 21: 2787-2796.
 87. Machiels K, Sabino J, Vandermosten L, Joossens M, Arijis I, de Bruyn M, Eeckhaut V, Van Assche G, **Ferrante M**, Verhaegen J, Van Steen K, Van Immerseel F, Huys G, Verbeke K, Wolthuis A, de Buck Van Overstraeten A, D'Hoore A, Rutgeerts P, Vermeire S. Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. *Gut* 2017; 66: 79-88.
 88. De Bie C, Ballet V, Hendriks N, Coenen S, Weyts E, Van Assche G, Vermeire S, **Ferrante M**. Smoking behaviour and knowledge of the health effects of smoking in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2015; 42: 1294-1302.
 89. Vidović D, Carlon MS, F da Cunha M, Dekkers JF, Hollenhorst MI, Bijvelds MJ, Ramalho AS, Van den Haute C, **Ferrante M**, Baekelandt V, Janssens HM, De Boeck K, Sermet-Gaudelus I, de Jonge HR, Gijsbers R, Beekman JM, Edelman A, Debyser Z. rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and CF Mice. *Am J Respir Crit Care Med* 2016; 193: 288-298.
 90. Bollen L, Vande Casteele N, Ballet V, Van Assche G, **Ferrante M**, Vermeire S, Gils A. Thromboembolism as an important complication of inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2016; 28: 1-7.
 91. Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, **Ferrante M**, Van Assche G, Rutgeerts P, Raes J. Donor species richness determines fecal microbiota transplantation success in inflammatory bowel disease. *J Crohns Colitis* 2016; 10: 387-394.
 92. Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Casteele NV, Breynaert C, Ballet V, **Ferrante M**, Noman M, Van Assche G, Rutgeerts P, van den Oord JJ, Gils A, Segaeert S, Vermeire S. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. *Ann Intern Med* 2015; 8:10-22.
 93. de Buck van Overstraeten A, Vermeire S, Vanbeckevoort D, Rimola J, **Ferrante M**, Van Assche G, Wolthuis A, D'Hoore A. Modified side-to-side isoperistaltic strictuoplasty over the ileocaecal valve: an alternative for ileocaecal resection in extensive terminal ileal Crohn's disease. *J Crohns Colitis* 2016; 10: 437-442.
 94. Papamichael K, Van Stappen T, Casteele NV, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, **Ferrante M**. Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis. *Clin Gastroenterol Hepatol* 2016; 14: 543-549.
 95. Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G, Vermeire S, **Ferrante M***, Gils A*. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis. *J Crohns Colitis* 2016; 10: 575-581.
 96. Coenen S, Weyts E, Ballet V, Noman M, Van Assche G, Vermeire S, Van Emelen J, **Ferrante M**. Identifying predictors of low adherence in patients with inflammatory bowel disease. *Eur J Gastroenterol Hepatol* 2016; 28: 503-507.
 97. De Bie C, **Ferrante M**. Letter: smoking as a modifiable risk factor for a complicated course in Crohn's disease. Authors' reply. *Aliment Pharmacol Ther* 2016; 43: 441.

98. Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, **Ferrante M**, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. *J Crohns Colitis* 2016; 10: 1015-1023.
99. Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, **Ferrante M**, Van Assche G, Van der Merwe S, Vermeire S, Raes J. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. *Gut* 2016; 65: 1681-1689.
100. Papamichael K, Baert F, Tops S, Van Assche G, Rutgeerts P, Vermeire S, Gils A, **Ferrante M**. Post-Induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis. *J Crohns Colitis* 2017; 11: 53-59.
101. Lemmens B, de Buck van Overstraeten A, Arijis I, Sagaert X, Van Assche G, Vermeire S, Tertychnyy A, Geboes K, Wolthuis A, D'Hoore A, De Hertogh G, **Ferrante M**. Submucosal plexitis as a predictive factor for postoperative endoscopic recurrence in patients with Crohn's disease undergoing a resection with ileocolonic anastomosis: results from a prospective single centre study. *J Crohns Colitis* 2017; 11: 212-220.
102. Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, **Ferrante M**, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet* 2016; 388: 1281-1290.
103. Billiet T, Dreesen E, Cleynen I, Wollants WJ, **Ferrante M**, Van Assche G, Gils A, Vermeire S. A genetic variation in the neonatal Fc-receptor affects anti-TNF drug concentrations in inflammatory bowel disease. *Am J Gastroenterol* 2016; 111: 1438-1445.
104. Billiet T, Cleynen I, Ballet V, **Ferrante M**, Van Assche G, Gils A, Vermeire S. Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. *Aliment Pharmacol Ther* 2016; 44: 673-683.
105. Jauregui-Amezaga A, Geerits A, Das Y, Lemmens B, Sagaert X, Bessissow T, Lobatón T, **Ferrante M**, Van Assche G, Bisschops R, Geboes K, De Hertogh G, Vermeire S. A Simplified Geboes Score for Ulcerative Colitis. *J Crohns Colitis* 2016; 11: 305-313.
106. Decock A, Van Assche G, Vermeire S, Wuyts W, **Ferrante M**. Sarcoidosis-Like Lesions: another paradoxical reaction to anti-TNF therapy? *J Crohns Colitis* 2017; 11: 378-383.
107. Wauters L, Billiet T, Papamichael K, Ballet V, Joniau S, Verschueren P, Silversmit G, Van Assche G, Vermeire S, **Ferrante M**. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment. *Eur J Gastroenterol Hepatol* 2017; 29: 84-90.
108. Breynaert C, de Bruyn M, Arijis I, Cremer J, Martens E, Van Lommel L, Geboes K, De Hertogh G, Schuit F, **Ferrante M**, Vermeire S, Ceuppens J, Opdenakker G, Van Assche G. Genetic Deletion of Tissue Inhibitor of Metalloproteinase-1/TIMP-1 Alters Inflammation and Attenuates Fibrosis in Dextran Sodium Sulphate-induced Murine Models of Colitis. *J Crohns Colitis* 2016; 10: 1336-1350.
109. Verstockt B, Van Assche G, Vermeire S, **Ferrante M**. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease. *Expert Opin Biol Ther* 2017; 17: 31-47.
110. Bian S, **Ferrante M**, Gils A. Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab. *AAPS J* 2016; 468-474.
111. van Gennep S, Sahami S, Buskens CJ, van den Brink GR, Ponsioen CY, D'Hoore A, de Buck van Overstraeten A, van Assche G, **Ferrante M**, Vermeire S, Bemelman WA, D'Haens GR, Löwenberg M. Comparison of health-related quality of life and disability in ulcerative colitis patients following restorative proctocolectomy with ileal pouch-anal anastomosis versus anti-tumor necrosis factor therapy. *Eur J Gastroenterol Hepatol* 2017; 29: 338-344.
112. Danese S, Fiorino G, Raine T, **Ferrante M**, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update. *J Crohns Colitis* 2017; 11: 26-34.
113. Van Stappen T, Bollen L, Vande Casteele N, Papamichael K, Van Assche G, **Ferrante M**, Vermeire S, Gils A. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. *Clin Transl Gastroenterol* 2016; 7: e206.
114. Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, Vermeire S, Van Assche G, **Ferrante M**. Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2017; 23: 318-324.

115. Coenen S, Weyts E, Vermeire S, **Ferrante M**, Noman M, Ballet V, Vanhaecht K, Van Assche G. Effects of introduction of an inflammatory bowel disease nurse position on the quality of delivered care. *Eur J Gastroenterol Hepatol* 2017; 29: 646-650.
116. Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bouguen G, Bourreille A, **Ferrante M**, Franchimont D, Frost K, Hebuterne X, Marshall JK, O'Shea C, Rosenfeld G, Williams C, Peyrin-Biroulet L. Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. *Inflamm Bowel Dis* 2017; 23: 333-340.
117. Van Steenberghe S, Bian S, Vermeire S, Van Assche G, Gils A, **Ferrante M**. Dose de-escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease - a nested case-control study. *Aliment Pharmacol Ther* 2017;45: 923-932.
118. Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, **Ferrante M**, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. *Lancet* 2017; 389: 1699-1709.
119. Boretto M, Cox B, Noben M, Hendriks N, Fassbender A, Roose H, Amant F, Timmerman D, Tomassetti C, Vanhie A, Meuleman C, **Ferrante M**, Vankelecom H. Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability. *Development* 2017; 144: 1775-1786.
120. Verstockt B, Deleenheer B, Van Assche G, Vermeire S, **Ferrante M**. A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. *Expert Opin Drug Saf* 2017; 16: 809-821.
121. Kopylov U, Papamichael K, Katsanos K, Waterman M, Bar-Gil Shitrit A, Boysen T, Portela F, Peixoto A, Szilagyi A, Silva M, Maconi G, Har-Noy O, Bossuyt P, Mantzaris G, Barreiro de Acosta M, Chaparro M, Christodoulou DK, Eliakim R, Rahier JF, Magro F, Drobne D, **Ferrante M**, Sonnenberg E, Siegmund B, Muls V, Thurm T, Yanai H, Dotan I, Raine T, Levin A, Israeli E, Ghalim F, Carbonnel F, Vermeire S, Ben-Horin S, Roblin X. Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study. *Inflamm Bowel Dis* 2017; 23: 1605-1613.
122. Billiet T, Cleyne I, Ballet V, Claes K, Princen F, Singh S, **Ferrante M**, Van Assche G, Gils A, Vermeire S. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. *Scand J Gastroenterol* 2017; 52: 1086-1092.
123. de Bruyn M, Breynaert C, Arijis I, De Hertogh G, Geboes K, Thijs G, Matteoli G, Hu J, Van Damme J, Arnold B, **Ferrante M**, Vermeire S, Van Assche G, Opdenakker G. Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease. *Nat Commun* 2017; 8: 15384.
124. Noman M, **Ferrante M**, Bisschops R, De Hertogh G, Van den Broeck K, Rans K, Rutgeerts PJ, Vermeire S, Van Assche G. Vedolizumab induces long term mucosal healing in patients with Crohn's disease and ulcerative colitis. *J Crohns Colitis* 2017; 11: 1085-1089.
125. Papamichael K, Castele NV, **Ferrante M**, Gils A, Cheifetz AS. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window. *Inflamm Bowel Dis* 2017; 23: 1510-1515.
126. de Buck van Overstraeten A, Eshuis EJ, Vermeire S, Van Assche G, **Ferrante M**, D'Haens GR, Ponsioen CY, Belmans A, Buskens CJ, Wolthuis AM, Bemelman WA, D'Hoore A. Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres. *Br J Surg* 2017; 104: 1713-1722.
127. Vancamelbeke M, Vanuytsel T, Farré R, Verstockt S, **Ferrante M**, Van Assche G, Rutgeerts P, Schuit F, Vermeire S, Arijis I, Cleyne I. Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2017; 23: 1718-1729.
128. Noben M, Verstockt B, de Bruyn M, Hendriks N, Van Assche G, Vermeire S, Verfaillie C, **Ferrante M**. Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease? *Gut* 2017; 66: 2193-2195.
129. Rivière P, **Ferrante M**. Management of postoperative Crohn's disease: missing pieces of the puzzle. *J Crohns Colitis* 2017; 11: 1291-1292.

130. **Ferrante M**, de Buck van Overstraeten A, Schils N, Moens A, Van Assche G, Wolthuis A, Vermeire S, D'Hoore A. Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. *J Crohns Colitis* 2017; 11: 1353-1361.
131. Bisschops R, Bessissow T, Dekker E, East JE, Parra-Blanco A, Ragunath K, Bhandari P, Rutter M, Schoon E, Wilson A, John JM, Van Steen K, Baert F, **Ferrante M**. Pit pattern analysis with high-definition chromoendoscopy and narrow-band imaging for optical diagnosis of dysplasia in patients with ulcerative colitis. *Gastrointest Endosc* 2017; 86: 1100-1106.
132. Verhaeghe L, Bruyneel L, Stragier E, **Ferrante M**, Dierickx D, Prenen H. The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study. *Ann Gastroenterol* 2017; 30: 654-663.
133. Bian S, Dreesen E, Tang HT, Compennolle G, Peeters M, Van Assche G, **Ferrante M**, Vermeire S, Gils A. Antibodies toward vedolizumab appear from the first infusion onward and disappear over time. *Inflamm Bowel Dis* 2017; 23: 2202-2208.
134. Dreesen E, Van Stappen T, Ballet V, Peeters M, Compennolle G, Tops S, Van Steen K, Van Assche G, **Ferrante M**, Vermeire S, Gils A. Anti-infliximab antibody concentrations can guide on treatment intensification in patients with Crohn's disease who lose clinical response. *Aliment Pharmacol Ther* 2017; 47: 346-355.
135. Noben M, Vanhove W, Arnauts K, Santo Ramalho A, Van Assche G, Vermeire S, Verfaillie C, **Ferrante M**. Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiology. *United European Gastroenterol J* 2017; 5: 1073-1081.
136. Arijis I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, **Ferrante M**, Schuit F, Van Assche G, Rutgeerts P, Vermeire S. Effect of vedolizumab (anti- $\alpha 4\beta 7$ -integrin) therapy on histological healing and mucosal gene expression in patients with UC. *Gut* 2018; 67: 43-52.
137. Van Stappen T, Vande Casteele N, Van Assche G, **Ferrante M**, Vermeire S, Gils A. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial. *Gut* 2018; 67: 818-826.
138. Bisschops R, Bessissow T, Joseph JA, Baert F, **Ferrante M**, Ballet V, Willekens H, Demedts I, Geboes K, De Hertogh G, Vermeire S, Rutgeerts P, Van Assche G. Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial. *Gut* 2018; 67: 1087-1094.
139. Bossuyt P, Debeuckelaere C, **Ferrante M**, de Buck van Overstraeten A, Vanbeckevoort D, Billiet T, Wolthuis A, Cleynen I, Van Assche G, D'Hoore A, Vermeire S. Risk Stratification for Surgery in Stricturing Ileal Crohn's Disease: The BACARDI Risk Model. *J Crohns Colitis* 2017; 12: 32-38.
140. Vanhove W, Nys K, Arijis I, Cleynen I, Noben M, De Schepper S, Van Assche G, **Ferrante M**, Vermeire S. Biopsy-derived intestinal epithelial cell cultures for pathway based stratification of patients with inflammatory bowel disease. *J Crohns Colitis* 2017; 12: 178-187.
141. Germain A, de Buck van Overstraeten A, Wolthuis A, **Ferrante M**, Vermeire S, Van Assche G, D'Hoore A. Outcome of restorative proctocolectomy with ileo-anal pouch for ulcerative colitis: effect of changes in clinical practice. *Colorectal Dis* 2017; 20: O30-O38.
142. Lightner AL, McKenna NP, Tse CS, Hyman N, Smith R, Ovsepyan G, Fleshner P, Crowell K, Koltun W, **Ferrante M**, D'Hoore A, Lauwers N, Verstockt B, Spinelli A, DiCandido F, Raffals LE, Mathis KL, Loftus EV Jr. Postoperative Outcomes in Ustekinumab-Treated Patients Undergoing Abdominal Operations for Crohn's Disease. *J Crohns Colitis* 2017; 12: 402-407.
143. Panés J, García-Olmo D, Van Assche G, Colombel JF, Reinisch W, Baumgart DC, Dignass A, Nachury M, **Ferrante M**, Kazemi-Shirazi L, Grimaud JC, de la Portilla F, Goldin E, Richard MP, Diez MC, Tagarro I, Leselbaum A, Danese S; ADMIRE CD Study Group Collaborators. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease. *Gastroenterology* 2017; 154: 1334-1342.
144. Bossuyt P, Debeuckelaere C, **Ferrante M**, Vanbeckevoort D, Billiet T, Wolthuis A, van Assche G, D'Hoore A, Vermeire S. The operative risk and natural history after the diagnosis of ileal penetrating Crohn's disease. *Eur J Gastroenterol Hepatol* 2018; 30: 539-545.
145. Pouillon L, **Ferrante M**, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S. Mucosal Healing and Long-term Outcomes of Patients With

- Inflammatory Bowel Diseases Receiving Clinic-based vs Trough Concentration-based Dosing of Infliximab. *Clin Gastroenterol Hepatol* 2018; 16: 1276-1283.
146. Struyve M, **Ferrante M**, Van Overbeke L, Meersseman W, Cassiman D. Unusual yellow scaly colonic mucosal appearance: Tangier disease. *Gastrointest Endosc* 2018; 88: 193-195.
 147. Verstockt B, **Ferrante M**, Vermeire S, Van Assche G. New treatment options for inflammatory bowel diseases. *J Gastroenterol* 2018; 53: 585-590.
 148. Peeters H, Louis E, Baert F, Dewit O, Coche JC, **Ferrante M**, Lambrecht G, Colard A, Van Gossum A, Bossuyt P, Moreels T, Vander Cruyssen B, Gils A, De Vos M. Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab. *Acta Gastroenterol Belg* 2018; 81: 15-21.
 149. Franchimont D, **Ferrante M**, Louis E, De Vos M, Dewit O, Van Hootegem P, Moreels T, Liefferinckx C, Bossuyt P, Baert F, Rahier JF, Vermeire S. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). *Acta Gastroenterol Belg* 2018; 81: 49-53.
 150. Van de Vondel S, Baert F, Reenaers C, Vanden Branden S, Amininejad L, Dewint P, Van Moerkercke W, Rahier JF, Hindryckx P, Bossuyt P, **Ferrante M**; Belgian IBD Research and Development (BIRD). Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study. *Inflamm Bowel Dis* 2018; 24: 1099-1105.
 151. De Vos M, Dhooghe B, Vermeire S, Louis E, Mana F, Elewaut A, Bossuyt P, Baert F, Reenaers C, Van Gossum M, Macken E, **Ferrante M**, Hindryckx P, Dewit O, Holvoet T, Franchimont D; Belgian Inflammatory Bowel Disease Research and Development (BIRD). Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists. *United European Gastroenterol J* 2018; 6: 439-445.
 152. Dreesen E, Verstockt B, Bian S, de Bruyn M, Compennolle G, Tops S, Noman M, Van Assche G, **Ferrante M**, Gils A, Vermeire S. Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2018; 16: 1937-1946.
 153. Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, **Ferrante M**. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. *Inflamm Bowel Dis* 2018; 24: 2442-2451.
 154. Bossuyt P, Baert F, D'Heygere F, Nakad A, Reenaers C, Fontaine F, Franchimont D, Dewit O, Van Hootegem P, Vanden Branden S, Lambrecht G, **Ferrante M**; Belgian IBD Research and Development Group. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort. *Inflamm Bowel Dis* 2018; 25: 156-162.
 155. Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G, Vermeire S, **Ferrante M**. TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients? *Gut* 2019; 68: 1531-1533.
 156. de Bruyn M, **Ferrante M**. Failure of MMP-9 antagonists in IBD: demonstrating the importance of molecular biology and well-controlled preclinical studies. *J Crohns Colitis* 2018; 12: 1011-1013.
 157. Feagan BG, Panés J, **Ferrante M**, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. *Lancet Gastroenterol Hepatol* 2018; 3:671-680.
 158. Lobatón T, Bessissow T, Ruiz-Cerulla A, De Hertogh G, Bisschops R, Guardiola J, Van Assche G, Vermeire S, **Ferrante M**. Prognostic value of histological activity in patients with ulcerative colitis in deep remission: A prospective multicenter study. *United European Gastroenterol J* 2018; 6: 765-772.
 159. Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, **Ferrante M**. Influence of early adalimumab serum levels on immunogenicity and long-term outcome

- of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing. *Aliment Pharmacol Ther* 2018; 48: 731-739.
160. Bronswijk M, de Hertogh G, **Ferrante M**. Edematous colitis of an unknown cause, diagnosis by pattern recognition. *Gastroenterology* 2019; 156: e12-e13.
 161. van Hoeve K, Dreesen E, Hoffman I, Van Assche G, **Ferrante M**, Gils A, Vermeire S. Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease. *J Crohns Colitis* 2018; 12: 1316-1325.
 162. Verstockt B, Vermeire S, Van Assche G, **Ferrante M**. When IBD is not IBD. *Scand J Gastroenterol* 2018; 12: 1316-1325.
 163. Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S, Franchimont D, Macken E, Nijs J, Posen A, Strubbe B, Van Hoetegem A, Van Moerkercke W, Vermeire S, **Ferrante M**; Belgian IBD Research and Development group (BIRD). Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. *J Crohns Colitis* 2019; 13: 12-18.
 164. Rivière P, Vermeire S, Irlès-Depe M, Van Assche G, Rutgeerts P, de Buck van Overstraeten A, Denost Q, Wolthuis A, D'Hoore A, Laharie D, **Ferrante M**. No Change in Determining Crohn's Disease Recurrence or Need for Endoscopic or Surgical Intervention With Modification of Rutgeerts' Scoring System. *Clin Gastroenterol Hepatol* 2019; 17: 1643-1645.
 165. Rivière P, Münch A, Michetti P, Chande N, de Hertogh G, Schoeters P, **Ferrante M**, Vermeire S, Van Assche G. Vedolizumab in refractory microscopic colitis: an international case series. *J Crohns Colitis* 2019; 13: 337-340.
 166. Vliebergh JH, Deprez PH, de Looze D, **Ferrante M**, Orlent H, Macken E, Christiaens P, Mana F, De Hertogh G, Willekens H, Bisschops R. Efficacy and safety of radiofrequency ablation of Barrett's esophagus in the absence of reimbursement: a multicenter prospective Belgian registry. *Endoscopy* 2019; 51: 317-325.
 167. Detrez I, Schops G, Lefrère J, Tops S, Van Assche G, Vermeire S, Van Moerkercke W, **Ferrante M**, Gils A. Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information. *AAPS J* 2018; 21: 10.
 168. Van den Berghe N, Verstockt B, Tops S, **Ferrante M**, Vermeire S, Gils A. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. *J Gastroenterol Hepatol* 2019; 34: 1175-1181.
 169. Verstockt B, Perrier C, De Hertogh G, Cremer J, Creyns B, Van Assche G, **Ferrante M**, Ceuppens JL, Vermeire S, Breynaert C. Effects of Epithelial IL-13R α 2 Expression in Inflammatory Bowel Disease. *Front Immunol* 2018; 9: 2983.
 170. van Hoeve K, Dreesen E, Hoffman I, Van Assche G, **Ferrante M**, Gils A, Vermeire S. Efficacy, pharmacokinetics and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory bowel disease. *Ther Drug Monit* 2019; 41: 317-324.
 171. van Hoeve K, Dreesen E, Hoffman I, Van Assche G, **Ferrante M**, Gils A, Vermeire S. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr* 2019; 68: 847-853.
 172. Dreesen E, Faelens R, Van Assche G, **Ferrante M**, Vermeire S, Gils A, Bouillon T. Optimising infliximab induction dosing for patients with ulcerative colitis. *Br J Clin Pharmacol* 2019; 85: 782-795.
 173. Roelandt P, Demedts I, Willekens H, Bessissow T, Braeye L, Coremans G, Cuyle PJ, **Ferrante M**, Gevers AM, Hiele M, Osselaer M, Tack J, Tejpar S, Ulenaers M, Van Assche G, Van Cutsem E, Van Gool S, Vannoote J, Vermeire S, Bisschops R. Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial. *Endoscopy* 2019; 51: 237-243.
 174. Verstockt S, De Hertogh G, Van der Goten J, Verstockt B, Vancamelbeke M, Machiels K, Van Lommel L, Schuit F, Van Assche G, Rutgeerts P, **Ferrante M**, Vermeire S, Arijis I, Cleyne I. Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease. *J Crohns Colitis* 2019; 13: 916-930.
 175. Verstockt B, Verstockt S, Creyns B, Tops S, Van Assche G, Gils A, Ceuppens JL, Vermeire S, **Ferrante M**, Breynaert C. Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease. *Aliment Pharmacol Ther* 2019; 49: 572-581.
 176. Verstockt B, Verstockt S, Dehairs J, Ballet V, Blevi H, Wollants WJ, Breynaert C, Van Assche G, Vermeire S, **Ferrante M**. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. *EBioMedicine* 2019; 40: 733-742.

177. Verstockt B, Dreesen E, Noman M, Outtier A, Van den Berghe N, Aerden I, Compernelle G, Van Assche G, Gils A, Vermeire S, **Ferrante M**. Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates. *J Crohns Colitis* 2019; 13: 864-872.
178. Vande Casteele N, Baert F, Bian S, Dreesen E, Compernelle G, Van Assche G, **Ferrante M**, Vermeire S, Gils A. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study. *J Crohns Colitis* 2019; 13: 1248-1256.
179. Moens A, Verstockt B, Machiels K, Bossuyt P, Verdonck A, Lagrou K, van Assche G, Vermeire S, Ferrante M. Clostridium difficile infection in inflammatory bowel disease: epidemiology over two decades. *Eur J Gastroenterol Hepatol* 2019; 31: 668-673.
180. Bislenghi G, **Ferrante M**, D'Hoore A. Anti-TNF and pouch surgery for ulcerative colitis: the ones who blame for more complications? *Curr Drug Targets* 2019; 20: 1349-1355.
181. Vancamelbeke M, Laeremans T, Vanhove W, Arnauts K, Ramalho AS, Farré R, Cleynen I, **Ferrante M**, Vermeire S. Butyrate does not protect against inflammation-induced loss of epithelial barrier function and cytokine production in primary cell monolayers from patients with ulcerative colitis. *J Crohns Colitis* 2019; 13: 1351-1361.
182. Verstockt B, Vermeire S, **Ferrante M**, Breyneart C. Editorial: biomarker predictors of non-response to TNF α antagonists - the quest continues. Authors' reply. *Aliment Pharmacol Ther* 2019; 49: 1091-1092.
183. Coenen S, Weyts E, Geens P, Vermeire S, **Ferrante M**, Vanhaecht K, Van Assche G. Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease. *Scand J Gastroenterol* 2019; 54: 592-596.
184. Bislenghi G, Wolthuis A, Van Assche G, Vermeire S, **Ferrante M**, D'Hoore A. Cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn's disease. *Expert Opin Biol Ther* 2019; 3:1-10.
185. Sabino J, Verstockt B, Vermeire S, **Ferrante M**. New biologics and small molecules in inflammatory bowel disease: an update. *Therap Adv Gastroenterol* 2019; 12: 1756284819853208.
186. Creyns B, Cremer J, Hoshino T, Geboes K, de Hertogh G, **Ferrante M**, Vermeire S, Ceuppens JL, Van Assche G, Breyneart C. Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13. *Sci Rep* 2019; 9: 10064.
187. Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B, Heremans R, Perneel L, Kobayashi H, Van Zundert I, Brems H, Cox B, **Ferrante M**, Uji-I H, Koh KP, D'Hooghe T, Vanhie A, Vergote I, Meuleman C, Tomassetti C, Lambrechts D, Vriens J, Timmerman D, Vankelecom H. Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. *Nat Cell Biol* 2019; 21: 1041-1051.
188. Dreesen E, Kantasiripitak W, Detrez I, Stefanović S, Vermeire S, **Ferrante M**, Bouillon T, Drobne D, Gils A. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis. *Inflamm Bowel Dis* 2020; 26: 570-580.
189. Bronswijk M, Moens A, Lenfant M, Tops S, Compernelle G, Van Assche G, Vermeire S, Gils A, **Ferrante M**. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. *Inflamm Bowel Dis* 2020; 26: 161.
190. Verstockt B, Verstockt S, Veny M, Dehairs J, Arnauts K, Van Assche G, De Hertogh G, Vermeire S, Salas A, **Ferrante M**. Expression Levels of 4 Genes in Colon Tissue Might be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2020; 18: 1142-1151.
191. Sandborn WJ, **Ferrante M**, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. *Gastroenterology* 2020; 158: 537-549.
192. Verstockt B, Mertens E, Dreesen E, Outtier A, Noman M, Tops S, Schops G, Van Assche G, Vermeire S, Gils A, **Ferrante M**. Influence of drug exposure on vedolizumab-induced endoscopic remission in anti-TNF naïve and anti-TNF exposed IBD patients. *J Crohns Colitis* 2020; 14: 332-341.
193. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T,

- Szapary P, Marano C; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2019; 381: 1201-1214.
194. Bossuyt P, Baert F, Coenegrachts JL, De Vos M, Dewit O, **Ferrante M**, Fontaine F, Mana F, Vandervoort J, Moreels T. Ulcerative colitis treatment : an insight into daily clinical practice. *Acta Gastroenterol Belg* 2019; 82: 365-372.
 195. de Bruyn M, Ringold R, Martens E, **Ferrante M**, Van Assche G, Opendakker G, Dukler A, Vermeire S. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor. *J Crohns Colitis* 2020; 14: 176-184.
 196. van Hoeve K, Hoffman I, D'Hoore A, **Ferrante M**, Vermeire S. Long-term outcome of immunomodulator use in pediatric patients with inflammatory bowel disease. *Dig Liver Dis* 2020; 52: 164-172.
 197. Cleyne I, Linsen L, Verstockt S, Verstockt B, Ballet V, Vandeput E, Van Assche G, **Ferrante M**, Van Landuyt K, Vermeire S, Ectors N. Inflammatory Bowel Disease (IBD)-A Textbook Case for Multi-Centric Banking of Human Biological Materials. *Front Med (Lausanne)* 2019; 6: 230.
 198. Moens A, van der Woude CJ, Julsgaard M, Humblet E, Sheridan J, Baumgart DC, Gilletta De Saint-Joseph C, Nancey S, Rahier JF, Bossuyt P, Cremer A, Dewit S, Eriksson C, Hoentjen F, Krause T, Louis E, Macken E, Milenkovic Z, Nijs J, Posen A, Van Hootegem A, Van Moerkercke W, Vermeire S, Bar-Gil Shitrit A, **Ferrante M**. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. *Aliment Pharmacol Ther* 2020; 51: 129-138.
 199. Verstockt B, Claeys C, De Hertogh G, Van Assche G, Wolthuis A, D'Hoore A, Vermeire S, **Ferrante M**. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience. *United European Gastroenterol J* 2019; 7: 1215-1225.
 200. Detrez I, Thomas D, Van Steen K, Ballet V, Peeters M, Hoylaerts MF, Van Assche G, Vermeire S, **Ferrante M**, Gils A. Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients. *J Clin Gastroenterol* 2020; 54: 819-825.
 201. Restellini S, Biedermann L, Hruz P, Mottet C, Moens A, **Ferrante M**, Schoepfer AM. Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding. *Digestion* 2020; 8: 1-16.
 202. Somers M, Bossuyt P, **Ferrante M**, Peeters H, Baert F; for BIRD (Belgian IBD Research and Development). Belgian IBD Research Group (BIRD) Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases. *J Crohns Colitis* 2020; 14: 680-685.
 203. **Ferrante M**, Sabino J. Efficacy of anti-JAK inhibitors in ulcerative colitis. *J Crohns Colitis* 2020; 14: S737-S745.
 204. Bossuyt P, Nakase H, Vermeire S, de Hertogh G, Eelbode T, **Ferrante M**, Hasegawa T, Willekens H, Ikemoto Y, Makino T, Bisschops R. Automatic, computer-aided determination of endoscopic and histological inflammation in patients with mild to moderate ulcerative colitis based on red density. *Gut* 2020; 69: 1778-1786.
 205. Bian S, Van den Berghe N, Vandersmissen L, Tops S, Vermeire S, **Ferrante M**, Gils A, Thomas D. Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations. *J Pharm Biomed Anal* 2020; 185: 113224.
 206. Verstockt B, **Ferrante M**. Editorial: a clinical decision tool to identify patients who might benefit most from intensified dosing in the biological era-getting nearer? *Aliment Pharmacol Ther* 2020; 51: 737-738.
 207. Coenen S, Nijns E, Weyts E, Geens P, Van den Bosch B, Vermeire S, **Ferrante M**, Vanhaecht K, Van Assche G. Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy. *Scand J Gastroenterol* 2020; 55: 287-293
 208. Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, **Ferrante M**, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J,

- Butler JW, Petersson J, Petralia F, Colombel JF. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. *Gastroenterology* 2020; 159: 139-147.
209. Bis lenghi G, **Ferrante M**, Sabino J, Verstockt B, Martin-Perez B, Fie uws S, Wolthuis A, Vermeire S, D'Hoore A. Short- and long-term outcomes following side-to-side strictu repleasty and its modification over the ileocecal valve for extensive Crohn's ileitis. *J Crohns Colitis* 2020; 14: 1378-1384.
210. Coenen S, Haeck M, **Ferrante M**, Noman M, Van Assche G, Vermeire S. Quality of care in an inflammatory bowel disease clinical trial center : a prospective study evaluating patients' satisfaction. *Acta Gastroenterol Belg* 2020; 83: 25-31.
211. Rivière P, Vermeire S, Irlés-Depe M, Van Assche G, Rutgeerts P, Denost Q, Wolthuis A, D'Hoore A, Laharie D, **Ferrante M**. Rates of Post-operative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies. *Clin Gastroenterol Hepatol* 2021; 19: 713-720.
212. Dragoni G, Ding N, Gecse KB, Mansfield JC, Kopylov U, Beaugerie L, Bossuyt P, Sebastian S, Milla M, Bagnoli S, Yassin NA, Bettenworth D, Burisch J, Hedin C, Gisbert JP, **Ferrante M**; Clinical Research Committee (ClinCom) of ECCO and Young ECCO Committee (Y-ECCO). The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. *Eur J Gastroenterol Hepatol* 2020; 32: 1062-1066.
213. Machiels K, Pozuelo Del Río M, Martínez-De la Torre A, Xie Z, Pascal Andreu V, Sabino J, Santiago A, Campos D, Wolthuis A, D'Hoore A, De Hertogh G, **Ferrante M**, Manichanh C, Vermeire S. Early postoperative endoscopic recurrence in Crohn's disease is characterized by distinct microbiota recolonization. *J Crohns Colitis* 2020; 14: 1535-1546.
214. Chan W, Kariyawasam VC, Kim S, Pudipeddi AV, Paramsothy S, Shim HH, Mourad FH, Ding N, **Ferrante M**, Leong RW. Gastroenterologists' preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey. *Eur J Gastroenterol Hepatol* 2020; 32: 976-983.
215. Kantasiripitak W, Van Daele R, Gijsen M, **Ferrante M**, Spriet I, Dreesen E. Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs? *Front Pharmacol* 2020; 11: 620.
216. de Bruyn JR, Bossuyt P, **Ferrante M**, West RL, Dijkstra G, Witteman BJ, Wildenberg M, Hoentjen F, Franchimont D, Clasquin E, van der Bilt JD, Tollens T, Bemelman WA, D'Hoore A, Duijvestein M, D'Haens GR; Dutch-Belgian DETECT study group. High-dose vitamin D does not prevent postoperative recurrence of Crohn's disease in a randomized placebo-controlled trial. *Clin Gastroenterol Hepatol* 2020; 35: 2294-2297.
217. Arnauts K, Verstockt B, Ramalho AS, Vermeire S, Verfaillie C, **Ferrante M**. Ex Vivo Mimicking of Inflammation in Organoids Derived From Patients With Ulcerative Colitis. *Gastroenterology* 2020; 159:1564-1567.
218. Stakenborg M, Verstockt B, Meroni E, Goverse G, De Simone V, Verstockt S, Di Matteo M, Czarnewski P, Villablanca EJ, **Ferrante M**, Boeckxstaens GE, Mazzone M, Vermeire S, Matteoli G. Neutrophilic HGF-MET signaling exacerbates intestinal inflammation. *J Crohns Colitis* 2020; 14: 1748-1758.
219. Creyns B, Cremer J, De Hertogh G, Boon L, **Ferrante M**, Vermeire S, Van Assche G, Ceuppens JL, Breynaert C. Fibrogenesis in chronic murine colitis is independent of innate lymphoid cells. *Immun Inflamm Dis* 2020; 8: 393-407.
220. Dubois E, Moens A, Geelen R, Sabino J, **Ferrante M**, Vermeire S. Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. *United European Gastroenterol J* 2020; 8: 933-941.
221. Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, **Ferrante M**, Flores-Suárez LF, Fritzler MJ, Invernizzi P, Jayne D, Jennette JC, Little MA, McAdoo SP, Novikov P, Pusey CD, Radice A, Salama AD, Savige JA, Segelmark M, Shoenfeld Y, Sinico RA, Sousa MJ, Specks U, Terrier B, Tzioufas AG, Vermeire S, Zhao MH, Bossuyt X. 2020 international consensus on ANCA testing beyond systemic vasculitis. *Autoimmun Rev* 2020; 19: 102618.
222. Lee HS, Vancamelbeke M, Verstockt S, Wilms T, Verstockt B, Sabino J, **Ferrante M**, Vermeire S, Cleynen I. Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. *Cells* 2020; 9: E1793.
223. Ramalho AS, Fürstová E, Vonk AM, **Ferrante M**, Verfaillie C, Dupont L, Boon M, Proesmans M, Beekman JM, Sarouk I, Cordero CV, Vermeulen F, De Boeck K; Belgian

- Organoid Project. Correction of CFTR function in intestinal organoids to guide treatment of Cystic Fibrosis. *Eur Respir J* 2020; 1902426.
224. Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, **Ferrante M**, Reinisch W. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. *Am J Gastroenterol* 2020; 115: 1236-1245.
 225. Stefanovic S, Detrez I, Compernelle G, Brouwers E, Sever N, Stabuc B, Smrekar N, Kurent T, Novak G, Kozelj M, **Ferrante M**, Gils A, Drobne D. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. *Eur J Gastroenterol Hepatol* 2020; 33: 54-61.
 226. Kobayashi T, Siegmund B, Le Berre C, Wei SC, **Ferrante M**, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis. *Nat Rev Dis Primers* 2020; 6: 74.
 227. Verstockt B, Verstockt S, Abdu Rahiman S, Ke BJ, Arnauts K, Cleynen I, Sabino J, **Ferrante M**, Matteoli G, Vermeire S. Intestinal receptor of SARS-CoV-2 in inflamed IBD tissue seems downregulated by HNF4A in ileum and upregulated by interferon regulating factors in colon. *J Crohns Colitis* 2021; 15: 485-498.
 228. Verstockt B, Van Hemelen M, Outtier A, Sabino J, Van Wijngaerden E, De Munter P, **Ferrante M**, Wilmer A, Vermeire S. Invasive nocardiosis, disseminated varicella zoster reactivation, and pneumocystis jiroveci pneumonia associated with tofacitinib and concomitant systemic corticosteroid use in ulcerative colitis. *J Gastroenterol Hepatol* 2020; 35: 2294-2297.
 229. Verstockt B, Boets L, Sabino J, Vermeire S, **Ferrante M**. Thiopurine monotherapy has a limited place in treatment of patients with mild-to-moderate Crohn's disease. *Gut* 2021; 70: 1416-1418.
 230. Sandborn WJ, **Ferrante M**, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis. *Clin Gastroenterol Hepatol* 2022; 20: 105-115.
 231. Creyns B, Jacobs I, Verstockt B, Cremer J, Ballet V, Vandecasteele R, Vanuytsel T, **Ferrante M**, Vermeire S, Van Assche G, Ceuppens JL, Breynaert C. Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium. *Front Immunol* 2020; 11: 1847.
 232. Walentynowicz M, Van de Pavert I, Coenen S, Fierens L, Vlaeyen J, von Leupoldt A, Van Oudenhove L, Vermeire S, Van Assche G, **Ferrante M**, Van Diest I. Worries and concerns of inflammatory bowel disease (IBD) patients in Belgium - a validation of the Dutch rating form. *Scand J Gastroenterol* 2020; 55: 1427-1432.
 233. Van den Berghe N, Verstockt B, Gils A, Sabino J, **Ferrante M**, Vermeire S, Declerck P, Thomas D. Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations. *J Crohns Colitis* 2021; 15: 988-993.
 234. Sudhakar P, Verstockt B, Cremer J, Verstockt S, Sabino J, **Ferrante M**, Vermeire S. Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis. *Inflamm Bowel Dis* 2021; 27: 870-886.
 235. Poletti M, Arnauts K, **Ferrante M**, Korcsmaros T. Organoid-based models to study the role of host-microbiota interactions in IBD. *J Crohns Colitis* 2021; 15: 1222-1235.
 236. Bislenghi G, Fieuws S, Wolthuis A, Vanbeckevoort D, **Ferrante M**, Sabino J, Vermeire S, D'Hoore A. Positioning strictureplasty in the treatment of extensive Crohn's disease ileitis: a comparative study with ileocecal resection. *Int J Colorectal Dis* 2021; 36: 791-799.
 237. Kantasiripitak W, Verstockt B, Alsoud D, Lobatón T, Thomas D, Gils A, Vermeire S, **Ferrante M**, Dreesen E. The Effect of Aging on Infliximab Exposure and Response in Patients with Inflammatory Bowel Diseases. *Br J Clin Pharmacol* 2021; 87: 3776-3789.
 238. Carels C, Wauters L, Outtier A, Baert F, Bossuyt P, Colard A, De Looze D, **Ferrante M**, Goegebuer A, Hauser B, Hilbrands R, Hoffman I, Keymeulen B, Paquot I, Ruytjens I, Simoens M, Thienpont C, Verreth A, Verstockt B, Vermeire S, Veereman G. Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes Mellitus. *Front Pediatr* 2021; 9: 624416.
 239. Verstockt S, Verstockt B, Machiels K, Vancamelbeke M, **Ferrante M**, Cleynen I, De Hertogh G, Vermeire S. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2021; 27: 1564-1575.

240. Prins MM, Verstockt B, **Ferrante M**, Vermeire S, Wildenberg ME, Koelink PJ. Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways. *Front Immunol* 2021; 12: 627535.
241. Cuyx S, Ramalho AS, Corthout N, Fieuws S, Fürstová E, Arnauts K, **Ferrante M**, Verfaillie C, Munck S, Boon M, Proesmans M, Dupont L, De Boeck K, Vermeulen F; Belgian Organoid Project. Rectal organoid morphology analysis (ROMA) as a promising diagnostic tool in cystic fibrosis. *Thorax* 2021; 76: 1146-1149.
242. **Ferrante M**, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR. Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study. *J Crohns Colitis* 2021; 15: 2001-2010.
243. Carretero C, Carbonnel F, **Ferrante M**, Knudsen T, Van Lent N, Lobo AJ, Negreanu L, Vojvodic A, Oliva S. Monitoring established Crohn's disease with pan-intestinal video capsule endoscopy in Europe: clinician consultation using the nominal group technique. *Curr Med Res Opin* 2021; 37: 1547-1554.
244. Outtier A, **Ferrante M**. Chronic Antibiotic-Refractory Pouchitis: Management Challenges. *Clin Exp Gastroenterol* 2021; 14: 277-290.
245. Wang Z, Verstockt B, Sabino J, Vermeire S, **Ferrante M**, Declerck P, Dreesen E. Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. *Br J Clin Pharmacol* 2022; 88: 323-335.
246. Jorissen C, Verstockt B, Schils N, Sabino J, **Ferrante M**, Vermeire S. Long-term clinical outcome after thiopurine discontinuation in elderly IBD patients. *Scand J Gastroenterol* 2021; 56: 1323-1327.
247. Bislenghi G, Sucameli F, Fieuws S, **Ferrante M**, Sabino J, Wolthuis A, Vermeire S, D'Hoore A. Non-conventional versus conventional stricturoplasties for Crohn's disease. A Systematic Review and Meta-analysis of Treatment Outcomes. *J Crohns Colitis* 2021; *in press*.
248. van Hoeve K, Tabib NSS, Dreesen E, Tops S, Hoffman I, Gils A, **Ferrante M**, Vermeire S. Infliximab Concentrations During Induction Are Predictive for Endoscopic Remission in Pediatric Patients With Inflammatory Bowel Disease Under Combination Therapy. *J Pediatr* 2022; 240: 150-157.
249. Walentynowicz M, van de Pavert I, Fierens L, Coenen S, Vlaeyen JWS, von Leupoldt A, Van Oudenhove L, Vermeire S, Van Assche G, **Ferrante M**, Van Diest I. Inflammatory Bowel Disease-related Behaviours [IBD-Bx] questionnaire: Development, validation, and prospective associations with fatigue. *J Crohns Colitis* 2021; *in press*.
250. Narula N, Wong ECL, Colombel JF, Sandborn WJ, **Ferrante M**, Marshall JK, Reinisch W, Dulai PS. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. *J Crohns Colitis* 2021; *in press*.
251. Faelens R, Wang Z, Bouillon T, Declerck P, **Ferrante M**, Vermeire S, Dreesen E. Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. *Pharmaceutics* 2021; 13: 1623.
252. Goessens L, Colombel JF, Outtier A, **Ferrante M**, Sabino J, Judge C, Saeidi R, Rabbitt L, Armuzzi A, Domenech E, Michalopoulos G, Cremer A, García-Alonso FJ, Molnar T, Karmiris K, Gecse K, Van Oostrom J, Löwenberg M, Farkas K, Atreya R, Ribaldone DG, Selinger C, Hoentjen F, Bihin B, Sebastian S; European COMBIO study group, Rahier JF. Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study. *United European Gastroenterol J* 2021; 9: 1136-1147.
253. Moens A, Verstockt B, Alsoud D, Sabino J, **Ferrante M**, Vermeire S. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD. *Inflamm Bowel Dis* 2021; *in press*.
254. Papamichael K, Afif W, Drobne D, Dubinsky MC, **Ferrante M**, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L; International Consortium for Therapeutic Drug Monitoring. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. *Lancet Gastroenterol Hepatol* 2022; 7: 171-185.

255. Kantasiripitak W, Wang Z, Spriet I, **Ferrante M**, Dreesen E. Recent advancements in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. *Expert Rev Clin Pharmacol* 2021; 14: 1455-1466.
256. Ding NS, Lee T, Bettenworth D, Cleyne I, Yassin NA, Burisch J, Armuzzi A, **Ferrante M**, Zagorowicz E, Mansfield J, Gesce K, Gisbert JP, Raine T. Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID): results from an international survey. *Eur J Gastroenterol Hepatol* 2021; 33: e837-e842.
257. Fierens L, Liefferinckx C, Hoefkens E, Lobatòn T, Dreesen E; DIAMOND Platform from the Belgian IBD Research; Development (BIRD) group, Sabino J, **Ferrante M**. Introduction of subcutaneous infliximab CT-P13 and vedolizumab in clinical practice: a multi-stakeholder position statement highlighting the need for post-marketing studies. *J Crohns Colitis* 2022; *in press*.
258. Panés J, Bouma G, **Ferrante M**, Kucharzik T, Nachury M, de la Portilla de Juan F, Reinisch W, Selvaggi F, Tschmelitsch J, Brett NR, Ladouceur M, Binek M, Hantsbarger G, Campbell-Hill S, Karki C, Buskens C. INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn's Disease Treated in the ADMIRE-CD Trial. *Inflamm Bowel Dis* 2022; *in press*.
259. D'Haens GR, Sandborn WJ, Loftus EV Jr, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panés J, Baert F, Colombel JF, **Ferrante M**, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S. Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results. *Gastroenterology* 2022; *in press*.
260. Decraene F, Blockmans D, **Ferrante M**. Severe necrotizing colitis in a 45-year old woman without a cardiovascular history. *Gastroenterology* 2022; *in press*.
261. Rivière P, Bislenghi G, Vermeire S, Domènech E, Peyrin-Biroulet L, Laharie D, D'Hoore A, **Ferrante M**. Postoperative Crohn's disease recurrence: time to adapt endoscopic recurrence scores to the leading surgical techniques. *Clin Gastroenterol Hepatol* 2022; *in press*.
262. Bislenghi G, **Ferrante M**, De Hertogh G, Sucameli F, Wolthuis A, Sabino J, Vermeire S, D'Hoore A. Proctocolectomy and ileal pouch-anal anastomosis for the treatment of collagenous colitis. *Clin J Gastroenterol* 2022; *in press*.
263. Sharara AI, Malaeb M, Lenfant M, **Ferrante M**. Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication? *Inflamm Intest Dis* 2021; 18; 7: 7-12.
264. Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, **Ferrante M**, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Gonzalez YS, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. *Gastroenterology* 2022; *in press*.
265. Vermeire S, Geboes K, van Hootegem P, van Assche G, **Ferrante M**, De Hertogh G, D'Hoore A, D'Haens G. In Memoriam: Emeritus Prof. Dr. Paul Rutgeerts (1948-2020). *Gastroenterology* 2022; *in press*.
266. **Ferrante M**, Schirbel A, Pierik MJ, Haas T, Flamant M, Khalifa A, Philip G, Cornillie F, Meehan AG, Govoni M. Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study. *Eur J Gastroenterol Hepatol* 2022; 34: 646-654.
267. Moens A, Sadat Seyed Tabib N, Ballet V, Sabino J, Vermeire S, **Ferrante M**. Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre. *Aliment Pharmacol Ther* 2022; *in press*.
268. Sudhakar P, Andrighetti T, Verstockt S, Caenepeel C, **Ferrante M**, Sabino J, Verstockt B, Vermeire S. Integrated analysis of microbe-host interactions in Crohn's disease reveals potential mechanisms of microbial proteins on host gene expression. *iScience* 2022; 25: 103963.
269. Verstockt B, Volk V, Jaeckel C, Alsoud D, Sabino J, Nikolaus S, Outtier A, Krönke N, Feuerhake F, De Hertogh G, Rosenstiel P, Vermeire S, Schreiber S, **Ferrante M**, Aden K. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis. *Aliment Pharmacol Ther* 2022; *in press*.

270. Alsoud D, De Hertogh G, Compernelle G, Tops S, Sabino J, **Ferrante M**, Thomas D, Vermeire S, Verstockt B. Real-world endoscopic and histologic outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis. *J Crohns Colitis* 2022; *in press*.

Non-peer reviewed journals:

1. Van Assche G, **Ferrante M**, Vermeire S, Rutgeerts P. The role and importance of endoscopic mucosal healing in Crohn's disease. *Techniques in gastrointestinal endoscopy* 2004; 6: 138-143.

Book chapters:

1. **Ferrante M**, Vermeire S. How do we identify patients needing early aggressive therapy and what should we use? In: Irving PM, Siegel CA, Rampton DS, Shanahan F, eds. *Clinical dilemmas in inflammatory bowel disease: new challenges*. 2nd ed. Wiley-Blackwell, Oxford, UK 2011: 117-120.
2. **Ferrante M**, Rutgeerts P. Infliximab for ulcerative colitis. In: Lichtenstein G. *Medical therapy of mucosal ulcerative colitis*. Springer, Heidelberg, Germany 2014: 175-184.
3. Vermeire S, **Ferrante M**, Rutgeerts P. How should we be using C-reactive protein and fecal markers, such as lactoferrin or calprotectin, in our patients? In: Rubin DT, Friedman S, Farraye FA. *Curbside consultation in IBD: 49 clinical questions*. 2nd updated ed. SLACK Incorporated, Thorofare, USA 2014: 29-32.
4. **Ferrante M**, Van Assche G. What endpoints should we aim for in inflammatory bowel disease medical therapy? In: Rubin DT, Friedman S, Farraye FA. *Curbside consultation in IBD: 49 clinical questions*. 2nd updated ed. SLACK Incorporated, Thorofare, USA 2014: 57-60.

Other publications:

1. **Ferrante M**. Book Review: *Fast Facts: Inflammatory Bowel Disease*, 2nd ed. *Gut* 2007; 56: 1332.

H-index Jan 2022: 55

May 24th 2022